BG-89894
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic MTAP-deleted Solid Tumors
Conditions
Advanced or Metastatic MTAP-deleted Solid Tumors
Trial Timeline
Oct 12, 2024 → Dec 30, 2028
NCT ID
NCT06568614About BG-89894
BG-89894 is a phase 1 stage product being developed by BeOne Medicines for Advanced or Metastatic MTAP-deleted Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06568614. Target conditions include Advanced or Metastatic MTAP-deleted Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced or Metastatic MTAP-deleted Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06568614 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced or Metastatic MTAP-deleted Solid Tumors